Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
作者信息
Gulácsi László, Brodszky Valentin, Baji Petra, Rencz Fanni, Péntek Márta
机构信息
Corvinus University of Budapest and HTA Consulting Budapest, Budapest, Hungary.
Flór Ferenc County Hospital, Kistarcsa, Hungary.
出版信息
Adv Ther. 2017 May;34(5):1234. doi: 10.1007/s12325-017-0538-3.
Abstract
摘要
相似文献
1
Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.《利妥昔单抗生物类似药CT-P10在风湿病学和癌症治疗中的应用：28个欧洲国家的预算影响分析》勘误
Adv Ther. 2017 May;34(5):1234. doi: 10.1007/s12325-017-0538-3.
2
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.利妥昔单抗生物类似药CT-P10在风湿病学和肿瘤学中的应用：28个欧洲国家的预算影响分析
Adv Ther. 2017 May;34(5):1128-1144. doi: 10.1007/s12325-017-0522-y. Epub 2017 Apr 10.
3
CT-P10 (Truxima™): A Rituximab Biosimilar.CT-P10（Truxima™）：一种利妥昔单抗生物类似药。
BioDrugs. 2017 Jun;31(3):275-278. doi: 10.1007/s40259-017-0226-5.
4
Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.利妥昔单抗生物类似药 CT-P10 的药代动力学、疗效和安全性。
Expert Rev Clin Pharmacol. 2017 Sep;10(9):923-933. doi: 10.1080/17512433.2017.1359537. Epub 2017 Aug 2.
5
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.生物类似药CT-P10与利妥昔单抗相比在先前未治疗的晚期滤泡性淋巴瘤患者中的疗效、药代动力学及安全性：一项随机、双盲、平行组、非劣效性3期试验
Lancet Haematol. 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14.
6
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.类风湿关节炎患者中，利妥昔单抗生物类似药CT-P10与原研利妥昔单抗多达两个疗程的疗效、安全性及药代动力学：一项I期随机对照试验第72周的结果
BioDrugs. 2017 Aug;31(4):357-367. doi: 10.1007/s40259-017-0232-7.
7
Clinical development of CT-P10 and other biosimilar cancer therapeutics.CT-P10及其他生物类似药癌症治疗药物的临床开发
Future Oncol. 2017 May;13(15s):31-44. doi: 10.2217/fon-2017-0155.
8
Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.跨癌症适应症外推生物类似药数据的科学依据：CT-P10案例研究
Future Oncol. 2017 May;13(15s):45-53. doi: 10.2217/fon-2017-0156.
9
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags.利妥昔单抗生物类似药CT-P10在开封小瓶中以及稀释后储存在聚烯烃袋中的延长稳定性。
Ann Pharm Fr. 2017 Nov;75(6):420-435. doi: 10.1016/j.pharma.2017.06.003. Epub 2017 Aug 4.
10
A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.保加利亚、捷克共和国、匈牙利、波兰、罗马尼亚和斯洛伐克克罗恩病中生物类似药英夫利昔单抗的预算影响模型
Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119-25. doi: 10.1586/14737167.2015.1067142. Epub 2015 Jul 10.
Zotero 插件